624734-26-5

Usage

Uses

Used in Pharmaceutical Industry:
Tert-butyl 3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,6-naphthyridine-6-carboxylate is used as a chemical intermediate for the synthesis of new drugs. Its unique structure allows for the development of compounds with specific biological activities, potentially leading to the creation of novel therapeutic agents.
Used in Agrochemical Industry:
In the agrochemical sector, tert-butyl 3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,6-naphthyridine-6-carboxylate is used as a building block for the design of new crop protection products. Its incorporation into chemical structures can enhance the effectiveness of pesticides or fungicides, contributing to improved agricultural yields and crop health.
Used in Medicinal Chemistry Research:
tert-butyl 3-(trifluoroMethyl)-5,6,7,8-tetrahydro-1,6-naphthyridine-6-carboxylate serves as a valuable research tool in medicinal chemistry, where it can be used to explore the structure-activity relationships of various biologically active molecules. Understanding how modifications to the compound's structure affect its interactions with biological targets can guide the development of more effective drugs.
Used in Chemical Synthesis:
Tert-butyl 3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,6-naphthyridine-6-carboxylate is utilized in the synthesis of complex organic molecules, where its unique functional groups can be selectively modified to create a wide range of chemical products with diverse applications.

Upstream product

• 624734-25-4 3-(trifluoromethyl)-5,8-dihydro-1,6-naphthyridin-7(6H)-one 
• 24424-99-5 di-tert-butyl dicarbonate 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 33252-63-0 2-hydroxy-5-(trifluoromethyl)pyridine 
• 624734-24-3 tert-butyl 7-oxo-3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,6-naphthyridine-8-carboxylate 
• 624734-23-2 tert-butyl methyl [3-cyano-5-(trifluoromethyl)pyridin-2-yl]malonate 
• 624734-22-1 2-chloro-5-(trifluoromethyl)pyridine-3-carbonitrile 
• 76041-73-1 3-bromo-5-(trifluoromethyl)pyridin-2-ol 
• 129904-48-9 2-hydroxy-5-(trifluoromethyl)nicotinaldehyde 
• 741736-95-8 3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,6-naphthyridine, hydrochloride salt 
• 631-61-8 ammonium acetate 

Downstream Products

• 741736-95-8 3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,6-naphthyridine, hydrochloride salt 
• 624734-27-6 3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,6-naphthyridine 

Relevant academic research and scientific papers

CHEMOKING RECEPTOR ANTAGONISTS

Disclosed herein are chemokine receptor antagonists of formula (I) wherein G1, X1, X2, and X3 are as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using such compounds and compositions are also described.

SPIROALKENE CARBOXAMIDE DERIVATIVES AND THEIR USE AS CHEMOKINE RECEPTOR MODULATORS

The present invention is directed to compounds of Formula (I) below, which are antagonists to the chemoattractant cytokine receptor 2 (CCR2), and/or 5 (CCR5), pharmaceutical compositions, and methods for use thereof.

Spiroalkene carboxamide derivatives and their use as chemokine receptor modulators

The present invention is directed to compounds of Formula (I) below, which are antagonists to the chemoattractant cytokine receptor 2 (CCR2), and/or 5 (CCR5), pharmaceutical compositions, and methods for use thereof.

CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2

The present invention comprises compounds of Formula (I). Wherein: R1, R2, R4, J, Q, and A are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).

Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity

The present invention is directed to compounds of the formula I: Wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X, n and the broken lines are as defined herein which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptor CCR-2.

ALKYLAMINO, ARYLAMINO, AND SULFONAMIDO CYCLOPENTYL AMIDE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

Compounds of the formula (I) which are modulators of chemokine receptor activity useful in the prevention or treatment of certain inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis, and pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which chemokine receptors are involved.

2,6-Disubstituted piperiddines as modulators

The present invention is further directed to compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R16, R17, R18, R19, R20, R21 and R22 are as defined herein) which are modulators of chemokine receptor activity and are useful in the prevention or treatment of certain inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which chemokine receptors are involved.

CCR-2 ANTAGONIST SALT

The present invention provides an efficient synthesis for the preparation of ((1R,3S)-3-isopropyl-3-{[3-(trifluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl]carbonyl}cyclopentyl)[(3S,4S)-3-m ethoxytetrahydro-2H-pyran-4-yl]amine and its succinate salt.

PROCESS FOR THE PREPARATION OF CCR-2 ANTAGONIST

The present invention provides an efficient synthesis for the preparation of ((1R,3S)-3-isopropyl-3- {[3-(trifluoromethyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl]carbonyl} cyclopentyl)[(3S,4S)-3-m ethoxytetrahydro- 2H-pyran-4-yl]amine and its succinate sal

AMINO HETEROCYCLIC MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

Compounds of Formula I and Formula II: (wherein n, R 1,R2, R3, R4, R5, R6, R7, R8, R9, R10, R15, R16, R17, R18, R19, R24, R25, R26, R27, R28, R29, R30, R33 R34, R35, R36, R37, R38, A, j, k, m, n, X, Y and Z are as defined herein) which are modulators of chemokine receptor activity and are useful in the prevention or treatment of certain inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which chemokine receptors are involved.